Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.

NCT00141934 is registered in ClinicalTrials.gov with Sosei as lead sponsor.

NCT NCT00141934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00141934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.
Lead sponsor
Sosei
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
Not reported
Enrollment
232
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis